Journal article
Neonatal Bacille Calmette-Guérin Vaccination and Infections in the First Year of Life: The MIS BAIR Randomized Controlled Trial
NL Messina, LF Pittet, K Gardiner, B Freyne, KL Francis, C Zufferey, V Abruzzo, C Morrison, KJ Allen, undefined Katie L Flanagan, AL Ponsonby, R Robins-Browne, F Shann, M South, P Vuillermin, S Donath, D Casalaz, N Curtis
Journal of Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2021
Abstract
Background: Bacille Calmette-Guérin (BCG) vaccination has beneficial off-target effects that may include protecting against non-mycobacterial infectious diseases. We aimed to determine whether neonatal BCG vaccination reduces lower respiratory tract infections (LRTI) in infants in the Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR) trial. Methods: In this investigator-blinded trial, neonates in Australia were randomized to receive BCG-Denmark vaccination or no BCG at birth. Episodes of LRTI were determined by symptoms reported in parent-completed, 3-month questionnaires over the first year of life. Data were analyzed by intention-to-treat using binary regression. R..
View full abstractGrants
Awarded by Murdoch Children's Research Institute
Funding Acknowledgements
MIS BAIR was funded by National Health and Medical Research Council (NHMRC) of Australia (GNT 1051228), The University of Melbourne, RCH Foundation, and the Murdoch Children's Research Institute. L. F. P. is supported by Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung (Early Postdoc Mobility Grant P2GEP3_178155).